Tags

Type your tag names separated by a space and hit enter

[Anti-interleukin-5 therapy for eosinophilic diseases].
Hautarzt. 2007 Feb; 58(2):122, 124-7.H

Abstract

In a number of diseases with eosinophilia, elevated interleukin (IL)-5 levels are detected in the peripheral blood and/or tissues. IL-5 plays an important role in regulating the production, differentiation, recruitment, activation, and survival of eosinophils. Therefore, neutralizing IL-5 by blocking antibodies seems a promising approach in the treatment of eosinophilic diseases. Clinical trials have demonstrated that anti-IL-5 therapy results in a rapid decrease in peripheral blood eosinophil numbers. Moreover, improvement of symptoms in patients with lymphocytic variants of hypereosinophilic syndromes, in eosinophilic esophagitis and chronic rhinitis with nasal polyposis has been observed. In contrast, in patients with bronchial asthma or atopic eczema, anti-IL-5 therapy showed only moderate or no clinical effects. Future studies will have to identify those eosinophilic diseases in which anti-IL-5 antibodies are effective, perhaps with the help of newly developed biomarkers.

Authors+Show Affiliations

Klinik und Poliklinik für Dermatologie und Venerologie, Inselspital, Universität Bern, 3010 Bern. dagmar.simon@insel.chNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

ger

PubMed ID

17221241

Citation

Simon, D, et al. "[Anti-interleukin-5 Therapy for Eosinophilic Diseases]." Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete, vol. 58, no. 2, 2007, pp. 122, 124-7.
Simon D, Braathen LR, Simon HU. [Anti-interleukin-5 therapy for eosinophilic diseases]. Hautarzt. 2007;58(2):122, 124-7.
Simon, D., Braathen, L. R., & Simon, H. U. (2007). [Anti-interleukin-5 therapy for eosinophilic diseases]. Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete, 58(2), 122, 124-7.
Simon D, Braathen LR, Simon HU. [Anti-interleukin-5 Therapy for Eosinophilic Diseases]. Hautarzt. 2007;58(2):122, 124-7. PubMed PMID: 17221241.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Anti-interleukin-5 therapy for eosinophilic diseases]. AU - Simon,D, AU - Braathen,L R, AU - Simon,H-U, PY - 2007/1/16/pubmed PY - 2007/8/19/medline PY - 2007/1/16/entrez SP - 122, 124-7 JF - Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete JO - Hautarzt VL - 58 IS - 2 N2 - In a number of diseases with eosinophilia, elevated interleukin (IL)-5 levels are detected in the peripheral blood and/or tissues. IL-5 plays an important role in regulating the production, differentiation, recruitment, activation, and survival of eosinophils. Therefore, neutralizing IL-5 by blocking antibodies seems a promising approach in the treatment of eosinophilic diseases. Clinical trials have demonstrated that anti-IL-5 therapy results in a rapid decrease in peripheral blood eosinophil numbers. Moreover, improvement of symptoms in patients with lymphocytic variants of hypereosinophilic syndromes, in eosinophilic esophagitis and chronic rhinitis with nasal polyposis has been observed. In contrast, in patients with bronchial asthma or atopic eczema, anti-IL-5 therapy showed only moderate or no clinical effects. Future studies will have to identify those eosinophilic diseases in which anti-IL-5 antibodies are effective, perhaps with the help of newly developed biomarkers. SN - 0017-8470 UR - https://www.unboundmedicine.com/medline/citation/17221241/[Anti_interleukin_5_therapy_for_eosinophilic_diseases]_ L2 - https://dx.doi.org/10.1007/s00105-006-1273-x DB - PRIME DP - Unbound Medicine ER -